News
The Pakistan Pharmaceuticals and Healthcare Report Provides Independent Forecasts and Competitive Intelligence on Pakistan's Pharmaceuticals and Healthcare Industry
DUBLIN, Ireland-(Business Wire)-March 14, 2008 - Research and Markets (http://www.researchandmarkets.com/reports/c86115) has announced the addition of "Pakistan Pharmaceuticals & Healthcare Report Q1 2008" to their offering.
With its large population and growing economy, Pakistan should be regarded as a significant emerging market for pharmaceutical firms. However, there are a multitude of deficiencies that discourage investment, such as intellectual property irregularities, availability of illegal Indian products, and discrimination against non-local companies. The current valuation of the market is US$1.5bn and we are forecasting 9% year-on-year growth through to 2012.
Pakistan has one of the highest prevalence of depression/anxiety in the world, placing a huge strain on its people. Causes include political insecurity, economic uncertainty and social disparities. Unfortunately a lack of trained psychiatrists and poor access to medication means that sufferers are not being treated effectively, resulting in a stunted economy and a considerable human cost. The author believes that there exists a distinct opportunity for manufacturers of psychotropic drugs, but they must be priced affordably given the country's low per capita spending.
The country is very active in forming partnerships with other countries, generally those at an equal or lower stage of development. During November 2007, a health services memorandum of understanding (MoU) was signed with Brunei. Cooperation between the two states will involve surgical procedures, training and the pharmaceutical industry. While highly beneficial to the sultanate, the pact does little for Pakistan's strong desire to increase medicine exports, given Bruneis small 385,000 population.
During Q407, a prominent professor from the Dow University of Health Sciences (DUHS) in Karachi said that doctors were succumbing to pressures from drugmakers to give out more expensive therapeutics when cheaper alternatives are available. This criticism was backed-up by the Pakistan Medical Association (PMA), which pointed out the popular painkiller Ponstan (mefenamic acid) was being sold by a foreign drugmaker for PKR1 (US$0.02) per tablet, while local firms sell generic versions for a third of that price.
The export sector received a boost in September 2007, when the government cut the import duty on pharmaceutical packaging from 15% to 10%. This will allow Pakistani drugmakers to make finished drugs for less money, giving them greater impetus to sell them overseas.
Contents:
Executive Summary
Pakistan Pharmaceutical Industry SWOT
Pakistan Political SWOT
Pakistan Economic SWOT
Pakistan Business Environment SWOT
Pharmaceutical Business Environment Ratings
Pharmaceutical Ratings - Revised Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Pakistan - Business Environment Ratings
Table: Business Environment Rankings
Limits Of Potential Returns
Risks To Realisation Of Returns
Pakistan - Market Summary
Regulatory Regime
Intellectual Property Regime
Table: Healthcare And Pharmaceutical Companies That Are Members Of The American Business Council Of Pakistan
Counterfeit Drugs
Pricing And Reimbursement Regime
Recent Pricing And Reimbursement Developments
Industry Trends And Developments
Pharmaceutical Sector
Table: Pakistan's Pharmaceutical Market In Q406
Domestic Industry
Multinational Sector
Traditional Medicine
Epidemiology
Research And Development
International Co-operation
Industry Forecast Scenario
Overall Market Forecast
Table: Pakistan's Drug Market Forecast Indicators
Key Growth Factors - Industry
Table: Pakistan's Health Expenditure Indicators
Key Growth Factors - Macroeconomic
Table: Pakistan - Economic Activity
Prescription Market Forecast
Table: Pakistan's Prescription Drugs Market Forecasts (US$mn unless otherwise stated)
OTC Market Forecast
Table: Pakistan's OTC Drugs Market Forecasts (US$mn unless otherwise stated)
Generics And Patented Market Forecasts
Table: Pakistan Generic Drugs Market Forecast Indicators
Export/Import Forecasts
Table: Pakistan's Trade Data And Trends (US$mn)
Other Healthcare Data Forecasts
Table: Other Healthcare Data Trends
Key Risks To our Forecast Scenario
Competitive Landscape
Company Profiles
Leading Multinational Manufacturers
GlaxoSmithKline
Pfizer
Abbott Laboratories
Novartis
Sanofi-Aventis
Merck & Co
Wyeth
Domestic Manufacturers
Hilton Pharma
Efroze Chemical Industries
Ferozsons Laboratories
BMI Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Sources
For more information visit http://www.researchandmarkets.com/reports/c86115
Search Our News Using Google Search
Can't find what you want? Try using Google:
